Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Corporate Update (December 2023)
8 slides from Marinomed Biotech's corporate update, Dec 18, 2023
Slide 1: Marinomed Biotech AG evaluates strategic options for Carragelose portfolio
Marinomed Biotech AG evaluates strategic options for Carragelose portfolio Conference Call December 18th, 2023 CEO Andreas Grassauer CSO Eva Prieschl-Grassauer CFO Pascal Schmidt
Slide 2: Core: Research & development and generation of IP
Core: Research & development and generation of IP At the center of Marinomed’s business model Research & Development Intellectual property Sale of Carragelose products Revenue through license deals Revenue through (upfront, milestones & royalties) sale of goods OUTSOURCED OUTSOURCED Late-stage clini
Slide 3: Carragelose business unit
Carragelose business unit Premium-quality medical device portfolio: from an idea to marketed products Carragelose business Carragelose revenues • B2B white label business model 12 • Active licensing contracts with multiple international companies • Outsourced production, regulatory, and marketing &
Slide 4: Carragelose is MDR-ready
Carragelose is MDR-ready MDR transition creates favorable environment for Carragelose products Transition period for existing medical devices under MDD May 2024 31.12.2028 MDR becomes effective end of transition period MDR requirements already accomplished by end of 2023 Process validation 3 batches
Slide 5: Evaluating strategic options for Carragelose business
Evaluating strategic options for Carragelose business Maximize value Concentrate on core Strategic options Leverage the full competencies and may include: potential of the Structured process with free-up resources for • Partnerships Carragelose an external advisor research, • Licence deals business
Slide 6: Marinomed's platforms & therapeutic areas
Marinomed’s platforms & therapeutic areas Increasing attention to assets that have significant revenue potential Universal blocking of viruses and allergens as well as Solubilization of poorly water-soluble compounds and moistening of mucosal tissues improving local onset of action Cough & Allergy E
Slide 7: Near term targets and plan for 2024
Near term targets and plan for 2024 Sustainable profitability planned starting in 2024 Carragelose® OTC business • US approval with potential launch by Procter & Gamble in the 2024/25 season • New partnerships including for allergy and eye care products • Evaluate strategic options for Carragelose b
Slide 8: www.marinomed.com
www.marinomed.com Contact IR: Stephanie Kniep, ir@marinomed.com PR: Lucia Ziegler, pr@marinomed.com International: Metrum Communications, Roland Mayrl, marinomed@metrum.at